Table 2 Relationship between PIK3CA mutation status and standard clinical, pathological, and biological features of breast cancer
From: PIK3CAmutation impact on survival in breast cancer patients and in ERα, PR and ERBB2-based subgroups
Number of patients (percentage) | ||||
|---|---|---|---|---|
Total population number (percentage) | PIK3CAwild-type | PIK3CA-mutated | Pvaluea | |
Total | 452 (100.0) | 301 (66.6) | 151 (33.4) | |
Age, years | ||||
≤ 50 | 96 (21.2) | 66 (21.9) | 30 (19.9) | NS |
> 50 | 356 (78.8) | 235 (78.1) | 121 (81.1) | |
SBR histological gradeb, c | ||||
I | 55 (12.4) | 26 (8.9) | 29 (19.3) | 0.00021 |
II | 228 (51.6) | 144 (49.3) | 84 (56.0) | |
III | 159 (36.0) | 122 (41.8) | 37 (24.7) | |
Lymph node statusd | ||||
0 | 115 (25.5) | 78 (26.0) | 37 (24.5) | |
1-3 | 237 (52.5) | 157 (52.3) | 80 (53.0) | |
> 3 | 99 (22.0) | 65 (21.7) | 34 (22.5) | NS |
Macroscopic tumor sizee | ||||
≤ 25 mm | 217 (48.8) | 135 (45.2) | 82 (56.2) | 0.029 |
> 25 mm | 228 (51.2) | 164 (54.8) | 64 (43.8) | |
ERα status | ||||
Negative | 117 (25.9) | 97 (32.2) | 20 (13.2) | 0.000014 |
Positive | 335 (74.1) | 204 (67.8) | 131 (86.8) | |
PR status | ||||
Negative | 194 (42.9) | 150 (49.8) | 44 (29.1) | 0.000028 |
Positive | 258 (57.1) | 151 (50.2) | 107 (70.9) | |
ERBB2 status | ||||
Negative | 351 (77.7) | 225 (74.8) | 126 (83.4) | 0.036 |
Positive | 101 (22.3) | 76 (25.2) | 25 (16.6) | |
Histology | ||||
Ductal | 388 (85.8) | 259 (86.0) | 129 (85.5) | NS |
Lobular | 29 (6.4) | 19 (6.3) | 10 (6.6) | |
Others | 35 (7.8) | 23 (7.7) | 12 (7.9) | |